A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases


The transfusion of regulatory T cells (Tregs) has been used in the clinic to successfully prevent graft vs. host disease and is currently being evaluated in the treatment of other autoimmune diseases, such as organ graft rejection, type 1 diabetes and multiple sclerosis. Prior to transfusion, adoptive regulatory T cell transfer requires the expansion of regulatory T cells in culture; this results in a mixed population of regulatory T cells that limits the effectiveness of the transferred cells.

Scientists at the NIH have developed a method that promotes the expansion of regulatory T cells that are longer lived, more stable, and more suppressive of the autoimmune response. By supplementing T cell cultures with DNA oligonucleotides, the inventors were able to enrich the regulatory T cell population that enhanced the suppression of the autoimmune response. This method has the potential to more effectively generate regulatory T cells for the treatment of autoimmune diseases.

Potential Commercial Applications: Competitive Advantages:
Treatment of autoimmune diseases, such as Graft vs. Host Disease, Organ Graft Rejection Type 1 Diabetes, Multiple Sclerosis.  
  • More effective therapy when compared to traditional T cell expansion methods.
  • Expansion method is inexpensive and similar to current methods.


Inventors:
Yong Chan Kim (NIAID)
Ethan Shevach (NIAID)


Intellectual Property:
US Application No. 61/576,837
US Application No. 13/716,900


Licensing Contact:
John Stansberry , Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325
Rockville , MD 20852
Email: js852e@nih.gov
Phone: 301-435-5236
Fax: 301-402-0220

OTT Reference No: E-279-2011/0

Updated: 09/28/2012